HealthTree Logo
search more_vert
App Logo
person Sign In / Create Account
Isatuximab Prolongs Progression Free Survival for Relapsed/Refractory Patients
Posted: Feb 05, 2019
Isatuximab Prolongs Progression Free Survival for Relapsed/Refractory Patients image
A new monoclonal antibody targeting CD38 has been working its way through clinical trials. In the Phase 3 trial, Isatuximab was found to prolong progression free survival when combined with pomalidomide and dexamethasone compared to pomalidomide and dexamethasone alone.

The study, known as ICARIA-MM, enrolled 307 patients with relapsed/refractory myeloma. All participants had received lenalidomide and a proteasome inhibitor. In the trial, isatuximab was given by IV once a week for four weeks, then every other week with pomalidomide and dex. 

The study results, which will be published at an upcoming medical meeting, are anticipated to help obtain regulatory approval  later this year. 

“We are excited by these results, which represent significant progress in our ambition to extend the lives of multiple myeloma patients,” said John Reed, Head of Research and Development at Sanofi. “We look forward to engaging with regulatory authorities with the goal of bringing this potential new treatment to patients as quickly as possible.”

Isatuximab is currently in more Phase 3 clinical trials which can be found here: 

Isatuximab Clinical Trials


This is a second drug targeting CD38 (same target as daratumumab). 


The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of HealthTree Foundation (formerly Myeloma Crowd). 

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Janssen Oncology
Adaptive Biotechnologies
Amgen Oncology

Follow Us

facebook instagram twitter youtube